Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results
Date:7/28/2009

X1032 from the European Medicines Agency.
  • Lexicon completed the multiple ascending-dose portion of a Phase 1 study of its LX4211 drug candidate to evaluate the safety, tolerability, and pharmacokinetics of LX4211 in healthy volunteers over a seven-day dosing period. Top-line results from the Phase 1 clinical trial will be available later this quarter.
  • Lexicon is preparing to initiate a Phase 2a study of LX2931 in patients with rheumatoid arthritis. Lexicon has identified the clinical trial sites for the Phase 2 study, and patient enrollment is expected to begin in the third quarter of 2009. In addition, Lexicon presented Phase 1 data for LX2931 at the European League Against Rheumatism (EULAR) annual meeting on June 13, 2009.
  • Lexicon continues to enroll patients in a Phase 2a clinical trial of its LX1031 drug candidate for non-constipating irritable bowel syndrome (IBS). Enrollment is on track to be completed by year-end. The trial is designed as a double-blind, randomized, placebo-controlled study to evaluate the safety and tolerability of LX1031 and its effects on symptoms associated with IBS. In addition, Lexicon presented Phase 1 data for LX1031 at the Digestive Disease Week (DDW) annual meeting on May 31, 2009.
  • Ajay Bansal, formerly of Tercica, Inc., was appointed executive vice president of corporate development and chief financial officer, responsible for leading the compa
    '/>"/>

    • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8

    Related medicine news :

    1. Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
    2. Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research
    3. Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
    4. Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
    5. Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors
    6. Hisamitsu Pharmaceutical Co., Inc. Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals, Inc.
    7. Webcast Alert: Isis Pharmaceuticals Second Quarter 2009 Financial Results Conference Call
    8. UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
    9. Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
    10. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
    11. EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/19/2013)... Alonso Krangle LLP a dedicated law ... lawsuit on behalf of a-24-year-old financial analyst rendered quadriplegic ... The diving accident lawsuit, which was filed in the Supreme ... Defendant held the property out as a bathing beach, but ... area. (Case No. 34556/12) , According to the diving accident ...
    (Date:5/19/2013)... Cheap Concert Tickets announces that ... in October will go on sale to the public Monday ... months of 2013, this legendary artist will be visiting prime ... “It’s Five O’clock Somewhere” they instantly remember the good ... their heads. Fortunately, fans can take a trip down memory ...
    (Date:5/19/2013)... (PRWEB) May 20, 2013 Seven-year-old Torin ... mission to overcome the limiting effects of autism. The ... Forestdale, MA, receive intensive applied behavior therapy (ABA) from ... (CARD), considered one the world’s most effective treatment centers ... was nonverbal, did not point or answer to his ...
    (Date:5/19/2013)... 2013 The three surgeons from the ... David A. Abrutyn, M.D., Robert S. Boretz, M.D., and ... at their current location, 215 Union Avenue, Suite B, ... in sports medicine, with emphasis on injuries of the ... adult patients for a wide range of orthopedic problems. ...
    (Date:5/19/2013)... Daily Gossip reporters have subjected Joel Marion ... That Burn Fat to a close analysis with the ... review is a detailed explanation of the diet ... , The two nutritionists have discovered during their research that ... caloric intake and expenditure of our body, that is, the ...
    Breaking Medicine News(10 mins):Health News:Alonso Krangle Files Diving Accident Lawsuit on Behalf of Suffolk County Man Rendered Quadraplegic in Tragic Diving Accident at Long Island Beach 2Health News:Alonso Krangle Files Diving Accident Lawsuit on Behalf of Suffolk County Man Rendered Quadraplegic in Tragic Diving Accident at Long Island Beach 3Health News:Jimmy Buffett Las Vegas Tickets: Jimmy Buffett Tickets in Vegas at the MGM Grand on Oct. 19 and Oct. 26 Go on Public Sale Monday, May 20 at 10:00 a.m. Local Time 2Health News:Jimmy Buffett Las Vegas Tickets: Jimmy Buffett Tickets in Vegas at the MGM Grand on Oct. 19 and Oct. 26 Go on Public Sale Monday, May 20 at 10:00 a.m. Local Time 3Health News:Boston Brother and Sister Battle Odds to Overcome Autism with Help from Center for Autism and Related Disorders 2Health News:Boston Brother and Sister Battle Odds to Overcome Autism with Help from Center for Autism and Related Disorders 3Health News:Boston Brother and Sister Battle Odds to Overcome Autism with Help from Center for Autism and Related Disorders 4Health News:Summit Medical Group Welcomes the Center for Orthopedic Care 2Health News:Summit Medical Group Welcomes the Center for Orthopedic Care 3Health News:The "17 Cheat Foods That Burn Fat" Review and Diet Plan Secrets Revealed by Daily Gossip 2
    ... Health Firm Sees Uptick in Employer Interest in Their ... caused businesses who regularly send their employees on international ... according to the owner of the state,s largest travel ... travel health issues, said Jamie Reesman, president of Passport ...
    ... Conference on the current global situationLONDON, May 21 ... be discussed during a web conference that Frost & ... pm BST.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )Aerospace ... current global situation and take a first look at ...
    ... an online lead generation company, announced today a partnership with Medical ... ... 21, 2009 -- The Oro Organization, LLC, an online lead generation ... the launch of our newest web property, USHairReplacement.com, we wanted to ...
    ... ability to provide affordable and timely transcription services , ... ... -- MxSecure, Inc., the nation,s leading provider of transcription services ... today it will incorporate M*Modal,s Conversational Documentation Services (CDS) ...
    ... Health Care Improvement Firm,s Sales Marketing EffortsSOUTH BEND, Ind., ... the addition of Al Vega as senior vice president ... the company at a time of continued growth and ... for the company. In particular, he will be responsible ...
    ... 20 The following is a statement of ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The Campaign ... (D-MA) for his leadership in introducing and advancing ... Administration (FDA) regulatory authority over tobacco products, including ...
    Cached Medicine News:Health News:H1N1 Scare Causes Businesses to Get Serious About Travel Health 2Health News:Airlines in Turbulence - Virus Outbreaks and their Impact on the Aviation Market 2Health News:Airlines in Turbulence - Virus Outbreaks and their Impact on the Aviation Market 3Health News:The Oro Organization, LLC Partners with Medical Hair Restoration to Launch New Website USHairReplacement.com 2Health News:MxSecure Expands Offerings with M*Modal Speech Recognition Solution 2Health News:MxSecure Expands Offerings with M*Modal Speech Recognition Solution 3Health News:Press Ganey Names Chief Sales and Marketing Officer 2Health News:Sen. Edward Kennedy Leads Fight to Protect America's Kids From Tobacco 2
    (Date:5/17/2013)... , May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... study, JAKARTA , examining the selective ... endpoint in both dose groups. The primary endpoint assessed ... volume. Consistent with data reported in previous trials, the ... vomiting. Full results will be presented at an upcoming ...
    (Date:5/17/2013)... May 17, 2013  Boston Scientific Corporation (NYSE: ... annual EuroPCR Scientific Program May 21-24 in ... present a particularly rich and diversified set of data ... , M.D., global chief medical officer, Boston Scientific.  ... presented, including the NG PROMUS trial, which evaluated our ...
    (Date:5/16/2013)...  PTC Therapeutics, Inc., today announced that it has ... U.S. Securities and Exchange Commission ("SEC") relating to the ... number of shares to be offered and the price ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) J.P. ... managers for the offering. Cowen and Company is acting ...
    Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
    ... TRIANGLE PARK, N.C. , May 6 Chimerix, Inc., ... Thomas A. Pitler , Ph.D., has joined the company as Vice ... , , ... of experience, combining skills in business development and strategic planning with ...
    ... Intercell AG (VSE: ICLL) today announced that it has signed an agreement ... discovery. The technology is based on expression cloning of monoclonal antibodies from ... treat infectious diseases. , , ... the agreed terms Intercell will pay EUR 15 million to ...
    Cached Medicine Technology:Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development 2Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development 3Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases 2
    ... Respiratory Products, ,Westmed designs, manufacturers and ... and Respiratory professionals. Our mission is to ... clinician's ability to deliver quality medical care ... line. , ,Our web site is ...
    ... achieves optimum lung penetration for maximum therapeutic ... 1.04-1.10 µ at 6-8 LPM. Latex-free components. ... ,As the world leader in airway management ... of proven technology by offering top brands ...
    ... need for makeshift, modified nebulizer setups to ... gathering parts when your patient is critical? ... the utmost in Heliox rescue therapy. In ... becoming the standard of care in hospitals ...
    ... nebulizers offer a spill-proof design and effective ... 45° angle. All medical nebulizers are free-standing ... of configurations are available., ,All Portex® ... ,Portex® medication nebulizers feature consistently fine misting ...
    Medicine Products: